Imaging biomarkers in DI-ILD (Bleomycin study)

  • Research type

    Research Study

  • Full title

    Functional and structural lung imaging for detection and monitoring of drug induced interstitial lung disease in patients undergoing Bleomycin treatment

  • IRAS ID

    283799

  • Contact name

    Stephen Bianchi

  • Contact email

    stephen.bianchi@nhs.net

  • Sponsor organisation

    Sheffield Teaching Hospitals NHS Fountation Trust

  • Duration of Study in the UK

    1 years, 3 months, 30 days

  • Research summary

    Drug induced interstitial lung disease (DIILD) can be caused by over 350 different drugs in humans. DIILD is a condition where inflammation and scarring occurs in the lung causing patients to become breathless. Bleomycin is a well-known drug often used in the treatment of testicular and ovarian cancer which can sometimes cause DIILD. The current methods to detect and track ILD, including breathing tests (spirometry) are not very sensitive in early disease or for detecting underlying cause. Advances in imaging tests including MRI and CT may allow more detailed assessment of the lungs and have a proven potential for the evaluation of the early changes seen in DIILD. The aim of the current study to compare established imaging measurements with standard breathing test measurements used in monitoring of patients receiving bleomycin and assess early bleomycin-induced pulmonary toxicity.

    In order to do this we propose to conduct an observational study of patients receiving bleomycin using standard assessments used in clinical practice such as spirometry and also MRI and CT scans. We would like to scan patients over a period of time after each chemotherapy cycle and also after they complete chemotherapy. We hope that the findings in this study will allow us to identify early changes caused by bleomycin using imaging methods which could then be carried forward into a larger study to allow for prognosis of disease.

  • REC name

    West Midlands - Coventry & Warwickshire Research Ethics Committee

  • REC reference

    21/WM/0053

  • Date of REC Opinion

    1 Apr 2021

  • REC opinion

    Further Information Favourable Opinion